These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 39118052)

  • 1. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5.
    Molina KC; Webb BJ; Kennerley V; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Aggarwal NR; Ginde AA
    BMC Infect Dis; 2024 Aug; 24(1):802. PubMed ID: 39118052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.
    Platzer M; Totschnig D; Karolyi M; Clodi-Seitz T; Wenisch C; Zoufaly A
    Wien Klin Wochenschr; 2024 Aug; 136(15-16):458-464. PubMed ID: 38884783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.
    Veronese N; Di Gennaro F; Frallonardo L; Ciriminna S; Papagni R; Carruba L; Agnello D; De Iaco G; De Gennaro N; Di Franco G; Naro L; Brindicci G; Rizzo A; Bavaro DF; Garlisi MC; Santoro CR; Signorile F; Balena F; Mansueto P; Milano E; Giannitrapani L; Fiordelisi D; Mariani MF; Procopio A; Lattanzio R; Licata A; Vernuccio L; Amodeo S; Guido G; Segala FV; Barbagallo M; Saracino A
    Sci Rep; 2024 Apr; 14(1):9303. PubMed ID: 38654033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study.
    Rajme-López S; Martinez-Guerra BA; Román-Montes CM; Tamez-Torres KM; Tello-Mercado AC; Tepo-Ponce KM; Segura-Ortíz Z; López-Aguirre A; Gutiérrez-Mazariegos ODR; Lazcano-Delgadillo O; Nares-López R; González-Lara MF; Kershenobich-Stalnikowitz D; Sifuentes-Osornio J; Ponce-de-León A; Ruíz-Palacios GM
    Ther Adv Infect Dis; 2024; 11():20499361241236582. PubMed ID: 38545451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge.
    Chesdachai S; Rivera CG; Cole KC; Teaford HR; Gonzalez Suarez ML; Larsen JJ; Ganesh R; Tulledge-Scheitel S; Razonable RR
    Sci Rep; 2024 Mar; 14(1):5430. PubMed ID: 38443438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
    Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
    Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    Cao Z; Gao W; Bao H; Feng H; Mei S; Chen P; Gao Y; Cui Z; Zhang Q; Meng X; Gui H; Wang W; Jiang Y; Song Z; Shi Y; Sun J; Zhang Y; Xie Q; Xu Y; Ning G; Gao Y; Zhao R
    N Engl J Med; 2023 Feb; 388(5):406-417. PubMed ID: 36577095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Butler CC; Hobbs FDR; Gbinigie OA; Rahman NM; Hayward G; Richards DB; Dorward J; Lowe DM; Standing JF; Breuer J; Khoo S; Petrou S; Hood K; Nguyen-Van-Tam JS; Patel MG; Saville BR; Marion J; Ogburn E; Allen J; Rutter H; Francis N; Thomas NPB; Evans P; Dobson M; Madden TA; Holmes J; Harris V; Png ME; Lown M; van Hecke O; Detry MA; Saunders CT; Fitzgerald M; Berry NS; Mwandigha L; Galal U; Mort S; Jani BD; Hart ND; Ahmed H; Butler D; McKenna M; Chalk J; Lavallee L; Hadley E; Cureton L; Benysek M; Andersson M; Coates M; Barrett S; Bateman C; Davies JC; Raymundo-Wood I; Ustianowski A; Carson-Stevens A; Yu LM; Little P;
    Lancet; 2023 Jan; 401(10373):281-293. PubMed ID: 36566761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Wynia MK; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele JD; Stocker HR; Wogu AF; Zane RD; Sokol RJ; Ginde AA
    Chest; 2023 May; 163(5):1061-1070. PubMed ID: 36441040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19.
    Lim S; Tignanelli CJ; Hoertel N; Boulware DR; Usher MG
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac389. PubMed ID: 36000003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge.
    Piccicacco N; Zeitler K; Ing A; Montero J; Faughn J; Silbert S; Kim K
    J Antimicrob Chemother; 2022 Sep; 77(10):2693-2700. PubMed ID: 35913836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody therapies against SARS-CoV-2.
    Focosi D; McConnell S; Casadevall A; Cappello E; Valdiserra G; Tuccori M
    Lancet Infect Dis; 2022 Nov; 22(11):e311-e326. PubMed ID: 35803289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients.
    Gottlieb RL; Vaca CE; Paredes R; Mera J; Webb BJ; Perez G; Oguchi G; Ryan P; Nielsen BU; Brown M; Hidalgo A; Sachdeva Y; Mittal S; Osiyemi O; Skarbinski J; Juneja K; Hyland RH; Osinusi A; Chen S; Camus G; Abdelghany M; Davies S; Behenna-Renton N; Duff F; Marty FM; Katz MJ; Ginde AA; Brown SM; Schiffer JT; Hill JA;
    N Engl J Med; 2022 Jan; 386(4):305-315. PubMed ID: 34937145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remdesivir for the Treatment of Covid-19 - Final Report.
    Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
    N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance.
    Nguyen TL; Collins GS; Spence J; Daurès JP; Devereaux PJ; Landais P; Le Manach Y
    BMC Med Res Methodol; 2017 Apr; 17(1):78. PubMed ID: 28454568
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.